CL2024000208A1 - Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer - Google Patents
Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncerInfo
- Publication number
- CL2024000208A1 CL2024000208A1 CL2024000208A CL2024000208A CL2024000208A1 CL 2024000208 A1 CL2024000208 A1 CL 2024000208A1 CL 2024000208 A CL2024000208 A CL 2024000208A CL 2024000208 A CL2024000208 A CL 2024000208A CL 2024000208 A1 CL2024000208 A1 CL 2024000208A1
- Authority
- CL
- Chile
- Prior art keywords
- gedatolisib
- week
- administration
- cancer
- period
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225707P | 2021-07-26 | 2021-07-26 | |
| US202163285327P | 2021-12-02 | 2021-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000208A1 true CL2024000208A1 (es) | 2024-07-19 |
Family
ID=82932627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000208A CL2024000208A1 (es) | 2021-07-26 | 2024-01-24 | Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12350276B2 (https=) |
| EP (1) | EP4376848A1 (https=) |
| JP (1) | JP2024529430A (https=) |
| KR (1) | KR20240040768A (https=) |
| AU (2) | AU2022320615B2 (https=) |
| CA (1) | CA3227191A1 (https=) |
| CL (1) | CL2024000208A1 (https=) |
| IL (1) | IL310243A (https=) |
| MX (1) | MX2024001266A (https=) |
| TW (1) | TW202320795A (https=) |
| WO (1) | WO2023009438A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025049962A1 (en) * | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| US20260053814A1 (en) * | 2024-08-21 | 2026-02-26 | Celcuity Inc. | Treatment regimens for gedatolisib in hormonally-driven disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| LT2294072T (lt) | 2008-05-23 | 2017-06-12 | Wyeth Llc | Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai |
| US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| MX338327B (es) | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| ES2881214T3 (es) | 2014-12-17 | 2021-11-29 | Pfizer | Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa |
| SI3672571T1 (sl) | 2017-08-25 | 2022-01-31 | Pfizer Inc. | Farmacevtska vodna raztopina, ki vsebuje 1-(4-((4-(dimetilamino) piperdin-1-il)karbonil)fenil)-3-(4-(4,6-dimorfolin-4-il-1,3, 5-triazin-2-il)fenil)sečnino |
| EP4249069B1 (en) | 2018-06-07 | 2025-11-19 | Pfizer Inc. | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| EP3863618A1 (en) * | 2018-10-08 | 2021-08-18 | F. Hoffmann-La Roche AG | Methods of treating cancer with pi3k alpha inhibitors and metformin |
-
2022
- 2022-07-25 CA CA3227191A patent/CA3227191A1/en active Pending
- 2022-07-25 EP EP22754997.9A patent/EP4376848A1/en active Pending
- 2022-07-25 US US17/872,721 patent/US12350276B2/en active Active
- 2022-07-25 IL IL310243A patent/IL310243A/en unknown
- 2022-07-25 AU AU2022320615A patent/AU2022320615B2/en active Active
- 2022-07-25 MX MX2024001266A patent/MX2024001266A/es unknown
- 2022-07-25 TW TW111127690A patent/TW202320795A/zh unknown
- 2022-07-25 WO PCT/US2022/038188 patent/WO2023009438A1/en not_active Ceased
- 2022-07-25 KR KR1020247005862A patent/KR20240040768A/ko active Pending
- 2022-07-25 JP JP2024504503A patent/JP2024529430A/ja active Pending
-
2024
- 2024-01-24 CL CL2024000208A patent/CL2024000208A1/es unknown
-
2025
- 2025-06-05 US US19/229,722 patent/US20250345342A1/en active Pending
- 2025-08-27 AU AU2025223785A patent/AU2025223785A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024529430A (ja) | 2024-08-06 |
| AU2025223785A1 (en) | 2025-09-18 |
| EP4376848A1 (en) | 2024-06-05 |
| AU2022320615B2 (en) | 2025-08-21 |
| US12350276B2 (en) | 2025-07-08 |
| TW202320795A (zh) | 2023-06-01 |
| US20230022525A1 (en) | 2023-01-26 |
| IL310243A (en) | 2024-03-01 |
| WO2023009438A1 (en) | 2023-02-02 |
| US20250345342A1 (en) | 2025-11-13 |
| CA3227191A1 (en) | 2023-02-02 |
| MX2024001266A (es) | 2024-04-16 |
| KR20240040768A (ko) | 2024-03-28 |
| AU2022320615A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000208A1 (es) | Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer | |
| CO6361942A2 (es) | Terapia de combinacion con epoxicetonas peptidicas | |
| AR055038A1 (es) | Metodo y compuesto para tratar enfermedades vasculares perifericas | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
| CO6592015A2 (es) | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal | |
| MX2019004402A (es) | Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes. | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2022017877A2 (es) | Terapia de combinación para amiloidosis de la ttr | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| CL2022001477A1 (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor | |
| MX2025014865A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| AR126566A1 (es) | Métodos para el tratamiento contra el cáncer con 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. | |
| MX2022001227A (es) | Metodos de tratamiento del cancer multifocal. | |
| MX2022010006A (es) | Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. | |
| NI201000185A (es) | Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer. | |
| PE20242177A1 (es) | Tratamiento del glioma de bajo grado con mirdametinib |